Michael D. Krepps. A poster presenting the final results of an investigator-sponsored study led by Dr. Steven J. Isakoff, MD, Ph.D. (Massachusetts General Hospital) titled: A Phase 1b study of PVX-410 Vaccine in Combination with...
Cambridge, MA - December 09, 2021 – OncoPep, Inc., a developer of transformative immunotherapeutics, announced $11 million in Series D funding. The Series D was led by Tera Science and Kukje Pharma with participation from SX Company and...
Cambridge, MA – November 09, 2021 – OncoPep, Inc. today announced it is expanding its Scientific Advisory Board with the addition of Carl Novina, MD, Ph.D. As the leader and founder of the Dana‐Farber/Harvard Cancer Institute’s...
BOSTON – October 15, 2020 – OncoPep, Inc. today announced a licensing agreement with MANA Therapeutics for use of its EDIFY™ platform for the development of an autologous multi-tumor antigen adoptive T cell therapy for the treatment...
BOSTON – August 8, 2018 – OncoPep, Inc. today announced the initiation of a Phase 1b clinical trial evaluating the safety and tolerability of PVX-410, an investigational multi-peptide cancer vaccine, for patients with smoldering...
BOSTON – February 22, 2017 -- OncoPep, Inc. today announced the initiation of a Phase 1b clinical trial evaluating its investigational vaccine product PVX-410for the treatment of patients with metastatic triple negative breast cancer...
BOSTON – November 28, 2016 -- OncoPep, Inc. announced that a Phase 1b clinical trial is underway to evaluate PVX-410, a multi-peptide therapeutic cancer vaccine, as an adjuvant treatment in patients who have completed all planned therapy...
BOSTON – November 28, 2016 -- OncoPep, Inc. today announced the initiation of a Phase 1b clinical trial evaluating PVX-410, a multi-peptide therapeutic cancer vaccine, in patients with moderate or high-risk for progression smoldering...
BOSTON – August 28, 2014 -- OncoPep, Inc., today announced the closing of $6.9 million in Series B financing from new and existing investors. The financing included participation from angel groups, family foundations and individuals, as...